The company commenced the Phase III clinical trial of ALD-101 to evaluate its ability to accelerate neutrophil and platelet engraftment following cord blood transplantation in these patients. ALD-101
The results are from a retrospective, pooled analysis of data from three placebo-controlled clinical trials (eight weeks, 13 weeks and 14 weeks long) of Lyrica in over 2,000
Under the terms of the agreement, Topcon Medical Japan will be the sole local distributor of OptiMedica’s Pascal (pattern scan laser) Photocoagulator system, a fully integrated pattern scan
Therapeutic activity of PRX302 was assessed using standardized symptom indices, namely, International Prostate Symptom Score (IPSS) and Quality of Life Scores (QoL). IPSS assesses the severity of seven
Under the collaboration, which is exclusive across the parathyroid hormone (PTH) field, Zelos will utilize Aegis’s patented Intravail permeation enhancer technology to develop an intranasal version of ZT-031
MKC-1 administered in combination with paclitaxel in a preclinical, orthotopic breast tumor model demonstrated synergistic tumor inhibition. The combination of MKC-1 and paclitaxel, but neither agent alone, demonstrated
Under the memorandum of understanding (MOU), Bio-Bridge Science will form a joint venture (JV) together with JR Scientific (JRS) and several other investors in China. The JV is
The patent for Biothermal Power Source for Implantable Devices, is the third issued patent licensed to Biophan from Biomed Solutions, and covers the generation of electrical power from
The results point to the ability of Homspera to enhance formation of early-stage blood cells from adult hematopoietic (blood-forming) stem cells. The studies, performed by University of Medicine
Under the licensing and development agreement, Pfizer will make an upfront payment to Avant of $40 million and will make a $10 million equity investment in Avant. Pfizer
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.